Blockade of tumor necrosis factor-α-converting enzyme improves experimental small intestinal damage by decreasing matrix metalloproteinase-3 production in rats

References

• Beutler BA. The role of tumor necrosis factor in health and disease. J Rheumatol 1999; Suppl 57: 16–21
   Google Scholar
• Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385: 729–33
   PubMed Web of Science ®Google Scholar
• Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, et al. Cloning of disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature 1997; 385: 733–5
   PubMed Web of Science ®Google Scholar
• Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996; 334: 1717–25
   PubMed Web of Science ®Google Scholar
• van Deventer SJ. A place of TACE. Gut 2002; 51: 5–6
   PubMed Web of Science ®Google Scholar
• Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 2001; 120: 622–35
   PubMed Web of Science ®Google Scholar
• Park WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004; 4: 617–29
   PubMed Web of Science ®Google Scholar
• Schuppan D, Hahn EG. Matrix metalloproteinases in the gut: inflammation hits the matrix. Gut 2000; 47: 12–4
   PubMed Web of Science ®Google Scholar
• von Lampe B, Barthel B, Coupland SE, Riecken EO, Rosewicz S. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 2000; 47: 63–73
   PubMed Web of Science ®Google Scholar
• Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387–92
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Iida M, Kuroki F, Hizawa K, Koga H, Fujishima M. Effect of diet on experimentally induced intestinal ulcer in rats: morphology and tissue leukotrienes. Gut 1994; 35: 1058–63
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Iida M, Nakamura S, Hizawa K, Kuroki F, Fujishima M. Preventive effect of immunosuppressive agents against indomethacin-induced small intestinal ulcers in rats. Dig Dis Sci 1994; 39: 787–95
   PubMed Web of Science ®Google Scholar
• Koga H, Aoyagi K, Matsumoto T, Iida M, Fujishima M. Experimental enteropathy in athymic and euthymic rats: synergistic role of lipopolysaccharide and indomethacin. Am J Physiol (Gastrointest, Liver Physiol) 1999; 276: G576–82
   Web of Science ®Google Scholar
• Tarumi K. Essential role of macrophages and macrophage-related proinflammatory cytokines in indomethacin-induced enteropathy in rats [English abstract in Japanese article]. Kawasaki Igakkaishi 2002; 28: 243–56
   Google Scholar
• Matsumoto T, Iida M, Nakamura S, Kuroki F, Hizawa K, Fujishima M. An animal model of longitudinal ulcer in the small intestine induced by intracolonically administrated indomethacin in rats. Gastroenterol Jpn 1993; 28: 10–7
   PubMedGoogle Scholar
• Anthony A, Pounder RE, Dhillon AP, Wakefield AJ. Similarities between ileal Crohn's disease and indomethacin experimental jejunal ulcers in the rat. Aliment Pharmacol Ther 2000; 14: 241–5
   PubMed Web of Science ®Google Scholar
• Vilaseca J, Salas A, Guarner F, Rodriguez R, Malagelada JR. Participation of thomboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis. Gastroenterology 1990; 98: 269–77
   PubMed Web of Science ®Google Scholar
• Lindsay J, Van Montfrans C, Brennan F, Van Montfrans C, et al. IL-10 gene therapy prevents TNBS-induced colitis. Gene Ther 2002; 9: 1715–21
   PubMed Web of Science ®Google Scholar
• Heuschkel RB, MacDonald TT, Montelone G, Bajaj-Elliott M, Smith JA, Pender SL. Imbalance of stromelysin-1 and tissue inhibitor of matrix metalloproteinase (TIMP)-1 in the mucosal lesions of children with inflammatory bowel disease. Gut 2000; 47: 57–62
   PubMed Web of Science ®Google Scholar
• Baugh MD, Perry MJ, Hollander AP, Davies DR, Cross SS, Lobo AJ, et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 1999; 117: 814–22
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA. Variability in risk of gastrointestinal complications with different nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104: 30S–4
   Google Scholar
• Loftus EV, Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004; 126: 1504–17
   PubMed Web of Science ®Google Scholar
• Iddan G, Meron G, Glukhovsky A, Swain P. Wireless capsule endoscopy. Nature 2000; 405: 417
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Yano T, Kita H, Sunada K, Ido K, Sugano K. New system of double-balloon enteroscopy for diagnosis and treatment of small intestinal disorders. Gastroenterology 2003; 125: 1556–7
   PubMed Web of Science ®Google Scholar
• Kirkegaard T, Hansen A, Bruun E, Bryskov J. Expression and localization of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut 2004; 53: 701–9
   PubMed Web of Science ®Google Scholar
• McKaig BC, McWilliam D, Watoson SA, Mahida YR. Expression and regulation of tissue inhibitor of matrix metalloproteinase-1 and matrix metalloproteinase by intestinal myofibroblasts in inflammatory bowel disease. Am J Pathol 2003; 162: 1355–60
   PubMed Web of Science ®Google Scholar
• Pender SL, Tikle SP, Docherty AJ, Howie D, Wathen NC, MacDonald TT. A major role of matrix metalloproteinases in T cell injury in the gut. J Immunol 1997; 158: 1582–90
   PubMed Web of Science ®Google Scholar
• Colon AL, Menchen LA, Hurtado O, De Cristobal J, Lizasoain I, Leza JC, et al. Implication of TNF-alpha convertase (TACE/ADAM17) in inducible nitric oxide synthase expression and inflammation in an experimental model of colitis. Cytokine 2001; 16: 220–6
   PubMed Web of Science ®Google Scholar
• Galardy RE, Grobelny D, Foellmer HG, Fernandez LA. Inhibition of angiogenesis by the matrix metalloprotease inhibitor N-[2R-2-(hydroxamidocarbonymethyl)-4-methylpentanoyl]]-L-tryptophan methylamide. Cancer Res 1994; 54: 4715–8
   PubMed Web of Science ®Google Scholar
• Johnson LL, Bornemeier DA, Janowicz JA, Chen J, Pavlovsky AG, Ortwine DF. Effect of species differences on stromelysin-1 (MMP-3) inhibitor potency. An explanation of inhibitor selectivity using homology modeling and chimeric proteins. J Biol Chem 1999; 274: 24881–7
   PubMed Web of Science ®Google Scholar
• Cheng M, De B, Almstead NG, Pikul S, Dowty ME, Dietsch CR, et al. Design and synthesis of piperazine-based, matrix metalloproteinase inhibitors. J Med Chem 1999; 42: 2295–314
   PubMed Web of Science ®Google Scholar
• van Deventer SJ. Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology 2001; 121: 1242–6
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121: 1088–94
   PubMed Web of Science ®Google Scholar
• Corazza N, Brunner T, Buri C, Rihs S, Imboden MA, Seibold I, et al. Transmembrane tumor necrosis factor is a potent inducer of colitis even in the absence of its secreted form. Gastroenterology 2004; 127: 816–25
   PubMed Web of Science ®Google Scholar
• Sykes AP, Bhogal R, Brampton C, Chander C, Whelan C, Parsons ME, et al. The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease. Aliment Pharmacol Ther 1999; 13: 1535–42
   PubMed Web of Science ®Google Scholar
• Brynskov J, Foegh P, Pedersen G, Ellervik C, Kirkegaard T, Bingham A, et al. Tumor necrosis factor-alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut 2002; 51: 37–43
   PubMed Web of Science ®Google Scholar
• Bzowska M, Jura N, Lassak A, Black RA, Bereta J. Tumour necrosis factor-α stimulates expression of TNF-α converting enzyme in endothelial cells. Eur J Biochem 2004; 271: 2808–20
   PubMedGoogle Scholar
• Amour A, Slocombe PM, Webster A, Butler M, Knight CG, Smith BJ. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 1998; 435: 39–44
   PubMed Web of Science ®Google Scholar
• Vaalamo M, Karjalainen-Lindberg ML, Saarialho-Kere U. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of MMP-3 (TIMP-3) in intestinal ulceration. Am J Pathol 1998; 152: 1005–14
   PubMed Web of Science ®Google Scholar
• Bertrand V, Guimbaud R, Tulliez M, Mauprivez C, Sogni P, Couturier D, et al. Increase in tumor necrosis factor-α production linked to the toxicity of indomethacin for the rat small intestine. Br J Pharmacol 1998; 124: 138594
   Google Scholar
• Reuter BK, Wallace JL. Phosphodiesterase inhibitors prevent NSAID enteropathy independently of effects on TNF-α release. Am J Physiol (Gastrointest, Liver Physiol) 1999; 40: G847–54
   Google Scholar
• Catrina AI, Lampa J, Ernestam S, af Klint E, Bratt J, Klarekog L, et al. Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology 2002; 41: 484–9
   PubMed Web of Science ®Google Scholar